Overview

A Study of LY2599506 in Patients With Type 2 Diabetes

Status:
Terminated
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to help answer the following questions: - To test if taking LY2599506 for 12 weeks controls blood sugar better than taking placebo for 12 weeks. - To evaluate the safety of LY2599506 in participants with diabetes. - To determine if LY2599506 has the ability to control blood sugar in participants with diabetes. - To determine how much LY2599506 should be given to participants. - To determine if LY2599506 has an effect on a participant's weight. The study design consists of 4 study periods: a screening period, a 4-week dose adjustment period, an 8-week treatment period, and a 4-week follow-up period.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company